Endoscopic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes endoscopic relapse compared with 5‐aminosalicylic acid (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical remission1 · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission1 compared with methotrexate (low certainty).
1 finding from 1 review
Clinical remission or improvement · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission or improvement compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes clinical remission compared with 5‐ASA or Sulfasalzine (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).
1 finding from 1 review
Fistula improvement or healing · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in fistula improvement or healing compared with placebo (low certainty).
1 finding from 1 review
Steroid sparing effect · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine probably leads to higher steroid sparing effect compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher maintenance of remission (sensitivity analysis excluding Candy 1995) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · maintenance of remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in maintenance of remission compared with mesalazine or sulfasalazine (low certainty).
1 finding from 1 review
Adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes adverse events compared with mesalazine or sulfasalazine (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with mesalazine or sulfasalazine (very low certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).
1 finding from 1 review